Sign In
U.S. Department of Health & Human Services
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Bebtelovimab
FAQs
Bebtelovimab Emergency Use Authorization | HHS/ASPR
related-resources
Currently selected
Toggle navigation
About ASPR
Overview
Mission and Key Priorities
Program Offices
Organization Chart
Budget and Funding
Leadership Biographies
ASPR Year in Review
Working with ASPR
Newsroom
Blog
Response Operations
Health Care Readiness
Medical Countermeasures and Biodefense
Tools
COVID-19
Related Resources
Bebtelovimab
ASPR Frequently Asked Questions: Allocation and Distribution of Bebtelovimab
Press Release:
Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron
COVID-19 Therapeutics Right-Nav
COVID-19 Therapeutics
Locating COVID-19 Therapeutics
Test to Treat
COVID-19 Therapeutics Locator for Providers
COVID-19 Therapeutics Thresholds by Jurisdiction
Product Resources
Product Resources
Therapeutics Clinical Implementation Guide
COVID-19 Therapeutics Decision Aid
Side-by-Side Outpatient Therapeutics Overview
Products Purchased by the U.S. Government
Bebtelovimab
Evusheld
Lagevrio (molnupiravir)
Paxlovid
Sotrovimab
REGEN-COV
Bamlanivimab/etesevimab
Bamlanivimab
Announcements
Important Updates
